Isolation of a High-affinity Stable Single-chain Fv Specific for Mesothelin from DNA-immunized Mice by Phage Display and Construction of a Recombinant Immunotoxin with Anti-tumor Activity

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1998 Jan 22

PMID 9435250

Citations 79

Authors

P S Chowdhury

J L Viner

R Beers

I Pastan

Affiliations

Soon will be listed here.

Abstract

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas, and several other types of human cancers. Because among normal tissues, mesothelin is present only on mesothelial cells, it represents a good target for antibody-mediated delivery of cytotoxic agents. In the present study mice were immunized with an eukaryotic expression vector coding for mesothelin. When high serum antibody titers were obtained, a phage display library was made from the splenic mRNA of these mice. After three rounds of panning on recombinant mesothelin, a single-chain Fv (scFv)-displaying phage was selected that bound specifically to recombinant mesothelin and mesothelin-positive cells. The scFv was used to construct an immunotoxin by genetically fusing it with a truncated mutant of Pseudomonas exotoxin A. The purified immunotoxin binds mesothelin with high affinity (Kd 11 nm), is stable for over 40 hr at 37 degrees C and is very cytotoxic to cells expressing mesothelin. It also produces regressions of tumors expressing mesothelin. This combination of selective cytotoxicity, high activity, and stability makes the immunotoxin a good candidate for development as a therapeutic agent. This work also shows that DNA immunization can be used to isolate and clone antibodies against epitopes present on human proteins in their native conformation.

Citing Articles

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells.

Wang P, Wang Y, Zhao X, Zheng R, Zhang Y, Meng R Signal Transduct Target Ther. 2025; 10(1):20.

PMID: 39809749 PMC: 11733243. DOI: 10.1038/s41392-024-02096-5.

ETV7 limits the antiviral and antitumor efficacy of CD8 T cells by diverting their fate toward exhaustion.

Cheng J, Xiao Y, Peng T, Zhang Z, Qin Y, Wang Y Nat Cancer. 2025; 6(2):338-356.

PMID: 39805956 DOI: 10.1038/s43018-024-00892-0.

Single chain fragment variable, a new theranostic approach for cardiovascular diseases.

Zahid R, Wang J, Cai Z, Ishtiaq A, Liu M, Ma D Front Immunol. 2024; 15:1443290.

PMID: 39735545 PMC: 11671482. DOI: 10.3389/fimmu.2024.1443290.

Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.

Torchiaro E, Cortese M, Petti C, Basirico M, Invrea F, DAndrea A J Transl Med. 2024; 22(1):1100.

PMID: 39627822 PMC: 11616334. DOI: 10.1186/s12967-024-05851-y.

Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals.

Liu Y, Zhang M, Shen X, Xia C, Hu F, Huang D Cell Prolif. 2024; 57(12):e13727.

PMID: 39136096 PMC: 11628735. DOI: 10.1111/cpr.13727.

References

Lin T, Webster R, Konigsberg W . Isolation and characterization of the C and D proteins coded by gene IX and gene VI in the filamentous bacteriophage fl and fd. J Biol Chem. 1980; 255(21):10331-7. View

Reiter Y, Brinkmann U, Lee B, Pastan I . Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 1996; 14(10):1239-45. DOI: 10.1038/nbt1096-1239. View

Brinkmann U, Pai L, Fitzgerald D, Willingham M, Pastan I . B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A. 1991; 88(19):8616-20. PMC: 52560. DOI: 10.1073/pnas.88.19.8616. View

Chang K, Pai L, Batra J, Pastan I, Willingham M . Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992; 52(1):181-6. View

Tang D, DeVit M, Johnston S . Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356(6365):152-4. DOI: 10.1038/356152a0. View

Chang K, Pai L, Pass H, Pogrebniak H, Tsao M, Pastan I . Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992; 16(3):259-68. DOI: 10.1097/00000478-199203000-00006. View

Marks J, Hoogenboom H, Griffiths A, Winter G . Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem. 1992; 267(23):16007-10. View

Marks J, Winter G . An artificial immune system for making antibodies. Behring Inst Mitt. 1992; (91):6-12. View

Buchner J, Pastan I, Brinkmann U . A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. 1992; 205(2):263-70. DOI: 10.1016/0003-2697(92)90433-8. View

10.

Press O, Eary J, Appelbaum F, Martin P, Badger C, Nelp W . Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993; 329(17):1219-24. DOI: 10.1056/NEJM199310213291702. View

11.

Yamaguchi N, Hattori K, Kojima T, Imai N, Ochi N . A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994; 269(2):805-8. View

12.

Reiter Y, Pai L, Brinkmann U, Wang Q, Pastan I . Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 1994; 54(10):2714-8. View

13.

Reiter Y, Brinkmann U, Kreitman R, Jung S, Lee B, Pastan I . Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 1994; 33(18):5451-9. DOI: 10.1021/bi00184a014. View

14.

Brinkmann U, Pastan I . Immunotoxins against cancer. Biochim Biophys Acta. 1994; 1198(1):27-45. DOI: 10.1016/0304-419x(94)90004-3. View

15.

Reiter Y, Kreitman R, Brinkmann U, Pastan I . Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer. 1994; 58(1):142-9. DOI: 10.1002/ijc.2910580123. View

16.

Reiter Y, Brinkmann U, Jung S, Lee B, Kasprzyk P, King C . Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem. 1994; 269(28):18327-31. View

17.

Donnelly J, Ulmer J, Liu M . Immunization with DNA. J Immunol Methods. 1994; 176(2):145-52. DOI: 10.1016/0022-1759(94)90308-5. View

18.

Brinkmann U, Chowdhury P, Roscoe D, Pastan I . Phage display of disulfide-stabilized Fv fragments. J Immunol Methods. 1995; 182(1):41-50. DOI: 10.1016/0022-1759(95)00016-4. View

19.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

20.

Pai L, Wittes R, Setser A, Willingham M, Pastan I . Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med. 1996; 2(3):350-3. DOI: 10.1038/nm0396-350. View